Skip to content

Released Nov 5, 2021, before the open

10-Q filed Nov 5, 2021, 36 days after period end · 0001564590-21-054754

Q3 2021 · 10-Q
Revenue$112.43M+1.3% vs Q3 2020−7.4% vs Q2 2021
Net Income-$2.17MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted$0.11−54.2% vs Q3 2020−8.3% vs Q2 2021
Gross Profit$84,121,000−0.7%
Operating Income-$313,000N/M
Operating Cash Flowderived$6,432,000−70.6%
Free Cash Flowderived$3,907,000−79.2%
Margins · derived
Gross margin74.8%−1.5 pt vs Q3 2020
Operating margin-0.3%−4.0 pt vs Q3 2020
Net margin-1.9%−6.1 pt vs Q3 2020

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019Q3 2018
Revenue$112.43M$110.99M$113.50M$111.71M
Net Income-$2.17M$4.65M-$40.50M-$1.21M
EPS Diluted$0.11$0.24-$2.14-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR